We are live on ! Find out more
SHPH icon

Shuttle Pharmaceuticals
SHPH

4 hedge funds and large institutions have $61.5K invested in Shuttle Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,798% more capital inflows, than outflows

Capital inflows: $50.1K | Capital outflows: $1.02K

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 → 4 (+1)

0.8% less ownership

Funds ownership: 1.65% → 0.85% (-0.8%)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
StoneX Group
StoneX Group
New York
+$25.6K
2
Renaissance Technologies
Renaissance Technologies
New York
+$14.3K
3
Virtu Financial
Virtu Financial
New York
+$10.2K

Top Sellers

Rank Fund Capital Flow
1
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$1.02K

SHPH Hedge Fund Activity: Q4 2023 in Review

4 of the 6,878 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q4 2023, worth a combined $61.5K — down 61% from $158K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SHPH positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was StoneX Group, opening a new position worth an estimated $25.6K. The largest seller was Federation des caisses Desjardins du Quebec, exiting entirely with an estimated $1.02K sold.

  • 4 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q4 2023, up from 3 in Q3 2023.
  • Funds reported $61.5K of Shuttle Pharmaceuticals stock for Q4 2023, down 61% quarter-over-quarter.
  • 3 funds opened new Shuttle Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +2 holders.
  • The largest Shuttle Pharmaceuticals buyer in Q4 2023 was StoneX Group, an estimated $25.6K added.
  • The largest Shuttle Pharmaceuticals seller in Q4 2023 was Federation des caisses Desjardins du Quebec, an estimated $1.02K sold.

Based on aggregated 13F filings for Q4 2023.